Zeynep Irem Ozay

Dr. Zeynep Irem Ozay

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2022 in Nutrition
Verified
Journal Article
Closed access
OSOsman Sutcuoglu
Osman Sutcuoglu
ZOZeynep Irem Ozay
Zeynep Irem Ozay
AÖAhmet Özet
Ahmet Özet
OYOzan Yazıcı
Ozan Yazıcı
NÖNuriye Özdemir
Nuriye Özdemir

26 January 2023 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
KYKadriye Bir Yücel
Kadriye Bir Yücel
ZOZeynep Irem Ozay
Zeynep Irem Ozay
OSOsman Sutcuoglu
Osman Sutcuoglu
OYOzan Yazıcı
Ozan Yazıcı
AÜAytug Üner
Aytug Üner
NÖNuriye Özdemir
Nuriye Özdemir

4 December 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
NSNICOLAS SAYEGH
NICOLAS SAYEGH
RGRyon P. Graf
Ryon P. Graf
Umang SwamiUmang Swami
Umang Swami
ZOZeynep Irem Ozay
Zeynep Irem Ozay
CCChadi Hage Chehade
Chadi Hage Chehade
NANeeraj Agarwal
Neeraj Agarwal
Purpose: Immune checkpoint inhibitors (ICI) have shown limited efficacy in unselected patients with metastatic castration-resistant prostate cancer (mCRPC). However, ICIs are approved for biomarker-defined subsets: microsatellite instability–high (MSI-H) and/or high tumor mutational burden (TMB-H). The efficacy of ICIs in TMB-H but not MSI-H disease remains unclear, and limited data exist evaluating ICI outcomes associated with blood-based MSI (bMSI) in mCRPC. Experimental Design: This study used the United States–based deidentified Flatiron Health–Foundation Medicine prostate cancer Clinico-Genomic Database. Patients with tissue-assessed MSI (tMSI) and TMB (tTMB) status by an algorithm supporting an FDA-approved CDx for pembrolizumab were included if treated with single-agent ICI. Separately, outcomes on ICI associated with bMSI were assessed, including if treated with single-agent ICI or taxane. Results: Among 2,965 patients with mCRPC, tMSI-H (3.2%) was nearly always also tTMB ≥10 mut/Mb (4.7%). In 84 ICI-treated patients, time to next treatment (TTNT) and overall survival (OS) were more favorable in tMSI-H with any TMB [TTNT HR, 0.18; 95% confidence interval (CI), 0.09–0.37 and OS HR, 0.32; 95% CI, 0.15–0.66] and tTMB ≥10 without tMSI-H (TTNT HR, 0.18; 95% CI, 0.04–0.48 and OS HR, 0.20; 95% CI, 0.05–0.77) compared with tTMB <10 without tMSI-H group. In intrapatient assessments, patients with tTMB ≥10 had more favorable TTNT with subsequent ICI versus prior taxane. Detection of bMSI-H was associated with more favorable TTNT on ICI (HR, 0.34; 95% CI, 0.14–0.83) and OS (HR, 0.21; 95% CI, 0.06–0.75) when tumor fraction ≥1%. Conclusions: These findings add support for tTMB and tMSI in predicting ICI monotherapy benefit in mCRPC and provide evidence supporting bMSI testing when tissue is unavailable.

1 April 2025 in JCO Oncology Practice
Verified
Journal Article
Closed access
ZOZeynep Irem Ozay
Zeynep Irem Ozay
Umang SwamiUmang Swami
Umang Swami
NANeeraj Agarwal
Neeraj Agarwal

3 April 2025 in Journal of Kidney Cancer
Verified
Journal Article
Open access
PDF file
MOMicah Ostrowski
Micah Ostrowski
YJYeonjung Jo
Yeonjung Jo
GGGeorges Gebrael
Georges Gebrael
CCChadi Hage Chehade
Chadi Hage Chehade
ZOZeynep Irem Ozay
Zeynep Irem Ozay
USUmang Swami
Umang Swami
Ipilimumab with nivolumab (Ipi + Nivo) and immune checkpoint inhibitors with tyrosine kinase inhibitors (ICI + TKI) are the first-line approved treatments for intermediate- and poor-risk metastatic clear cell renal cell carcinoma (mccRCC); however, they have not been compared head-to-head in prospective trials to guide treatment selection. Thereupon, we sought to compare survival outcomes of patients receiving first-line Ipi + Nivo versus ICI + TKI, using a large, real-world database among patients with intermediate- and poor-risk mccRCC. This retrospective cohort study used a nationwide electronic health record-derived deidentified database, where patients with mccRCC with intermediate- or poor-risk who received first-line Ipi + Nivo or ICI + TKI between 20 June, 2016, and 26 January, 2023, were included. Primary outcomes were real-world time to next therapy (rwTTNT) and real-world overall survival (rwOS), summarized via Kaplan-Meier survival estimates with 95% confidence intervals (CIs) and compared in the context of propensity score (PS) matching weighted analysis. Of the 12,707 patients in the dataset, 1,438 with mccRCC met eligibility and were included. After PS matching weighted analysis, no significant difference in rwOS was noted between both groups (HR 1.01, 95% CI 0.86–1.19; p = 0.91); however, rwTTNT was significantly shorter with Ipi + Nivo than with ICI + TKI (HR 0.78, 95% CI 0.68–0.89; p < 0.001). In this large real-world study, there was evidence that rwOS was comparable, while rwTTNT was superior in patients receiving ICI + TKI compared to those receiving Ipi + Nivo. These real-world data offer important guidance for clinicians in choosing between Ipi + Nivo and ICI + TKI as frontline treatment.

16 June 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
CCChadi Hage Chehade
Chadi Hage Chehade
RGRyon P. Graf
Ryon P. Graf
ZOZeynep Irem Ozay
Zeynep Irem Ozay
GGGeorges Gebrael
Georges Gebrael
NSNICOLAS SAYEGH
NICOLAS SAYEGH
Umang SwamiUmang Swami
Umang Swami
Purpose: Homologous recombination/DNA damage repair (HRR) alterations (HRRalt) are found in around 30% of patients with advanced prostate cancer and have been associated with worse prognosis in the metastatic castrate-resistant setting. However, there are limited data with regard to their association with outcomes of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Experimental Design: This study used a de-identified nationwide (U.S.-based) prostate cancer clinico-genomic database. Patients with de novo mHSPC treated with androgen deprivation therapy intensification with either an androgen receptor pathway inhibitor (ARPI) or a taxane who underwent tissue biopsy within 90 days of mHSPC diagnosis were included. Time to castrate resistance (TTCR) and overall survival (OS) were compared between patients with non-altered HRR and those with HRRalt in any of 14 prespecified genes per the olaparib monotherapy FDA label. TTCR and OS indexed from mHSPC diagnosis were evaluated with Cox proportional hazard models adjusted for baseline prognostic factors. Results: Of 637 eligible patients included in our analysis, 181 harbored HRRalt (28.4%). Compared with patients with non-altered HRR, those with HRRalt had less favorable TTCR when treated with an ARPI [adjusted HR (aHR) = 1.58; 95% confidence interval (CI), 1.17–2.14] or a taxane (aHR = 1.77; 95% CI, 1.3–2.4). Additionally, OS was directionally less favorable in patients with HRRalt (ARPI: aHR = 1.12; 95% CI, 0.80–1.57 and taxane: aHR = 1.23; 95% CI, 0.88–1.72). Conclusions: To date, this is the largest real-world natural history study evaluating the association of HRRalt with outcomes in the mHSPC setting. These data may inform future clinical trial design and counseling of these patients. See related commentary by Graham and Yu, p. 4001